Stockscreener 앱 받기
1.19
1.72%
0.03
전일 마감가:
$1.16
열려 있는:
$1.18
하루 거래량:
25,118
Relative Volume:
0.01
시가총액:
$5.00M
수익:
-
순이익/손실:
$-16.08M
주가수익비율:
-0.5385
EPS:
-2.21
순현금흐름:
$-11.54M
1주 성능:
-12.59%
1개월 성능:
+58.82%
6개월 성능:
-36.56%
1년 성능:
-88.02%
1일 변동 폭
$1.18
$1.20
1주일 범위
$1.12
$1.34
52주 변동 폭
$0.5933
$12.00
Bio Path Holdings Inc Stock (BPTH) Company Profile
명칭
Bio Path Holdings Inc
전화
(832) 742-1357
주소
4710 BELLAIRE BOULEVARD, BELLAIRE, TX
BPTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
1.188 | 5.00M | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.27 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.25 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
622.80 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.28 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.50 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 개시 | ROTH Capital | Buy |
| 2017-11-13 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-04-18 | 개시 | Rodman & Renshaw | Buy |
| 2014-06-02 | 재개 | Maxim Group | Buy |
| 2014-05-09 | 개시 | Maxim Group | Buy |
모두보기
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Is This Penny Stock a Buy After a 180% Rally? - MSN
Is This Penny Stock A Buy After A 180% Rally? - Barchart
Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - Asianet Newsable
Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com
Bio-Path Holdings: Promising Preclinical Results for BP1001-A - TipRanks
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Benzinga
Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch
Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile
Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga
Innovative therapies and military tech drive early trading gains - RagingBull
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Artificial Intelligence (AI) News Live Feed - StockTitan
Wall Street-Heavily Traded - WDRB
Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph
Clinical Trials News Live Feed - StockTitan
Bio-Path reports potential obesity treatment success - Investing.com
Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN
Bullfrog AI CFO Passes Away - Defense World
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World
Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard
Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks
CNB Financial Services, Inc. goes ex dividend tomorrow - MSN
VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa
Stonegate Capital Partners Updates Coverage on Aemetis, Inc. (AMTX) Q3 2024 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges - Investing.com India
Tecnoglass Sets Record Date for Previously-Announced 36% Increase to Fourth Quarter 2024 Dividend - The Manila Times
Bio-Path Pivots to Diabetes Drug Development, Unveils Strategic Shift in Clinical Pipeline - StockTitan
BPTH stock touches 52-week low at $0.6 amid sharp annual decline - Investing.com Canada
Full Stock Market News from 2024-12-06 - StockTitan
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path Holdings Expands DNAbilize® Technology Applications - MSN
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Meridianbet (GMGI) and Crvena Zvezda Seal Euroleague's First Logo Integration Deal - Newsfile
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy - Yahoo Finance
Bio Path Holdings Inc (BPTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.19%
자본화:
|
볼륨(24시간):